We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.15 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
TIDMAMP
RNS Number : 6188I
Amphion Innovations PLC
09 August 2019
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Directorate Change
London and New York, 9 August 2019 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that Philip Tansey and Stephen Austin have resigned as Non-executive Directors and will leave the Board with immediate effect.
The Company has begun the process of seeking suitable candidates to fill these positions and will update shareholders accordingly.
Richard C.E. Morgan, Chief Executive Officer of Amphion said: "I would like to thank both Philip and Stephen for their service to Amphion. We wish them both well for the future."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224 Charlie Morgan Panmure Gordon Limited (Nominated Adviser Tel: +44 (0)20 and Corporate Broker) 7886 2500 Emma Earl/ Freddy Crossley (Corporate Finance) Charles Leigh-Pemberton (Corporate Broking) SP Angel Corporate Finance LLP (Joint Corporate Tel: +44 (0) 20 Broker) 3470 0470 David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com Anna Dunphy / Paul McManus
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOAGMGGRKLKGLZM
(END) Dow Jones Newswires
August 09, 2019 11:14 ET (15:14 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
